The New Zealand Brain Tumor Trust

Clinical Trials

A new clinical trial for brain tumour patients

There are limited clinical trials for brain tumour patients in New Zealand. The NZBTT wants to change this.

A clinical trial based at Dunedin Hospital will investigate if a new type of brain scan using a drug to treat iron deficiency can better image brain tumours before surgery.  If successful, the scan could help improve imaging and removal of brain tumours in the future. 

A clinical trial based at Dunedin Hospital is investigating if a new type of brain scan using a drug to treat iron deficiency can better image brain tumours before surgery.  If successful, the scan could help improve imaging and removal of brain tumours in the future. 

Brain immune cells uptake antigens/foreign particles including an iron formulation. The iron formulation contains ultrasmall iron oxide particles with diameter of 30 nm It is approved for intravenous use for the treatment of iron deficiency anemia in those with chronic kidney disease and when used off label, a MRI contrast agent. After intravenous infusion of iron particles diffuse into the glioblastoma extracellular space they passively extravasate into tissue (based on the leaky brain blood barrier), or are actively internalized by immune cells. The iron can then be imaged using MRI. Iron shows enhanced MRI imaging in necrotic regions in animal tumour models and in sarcoma patients.

 

A pilot study of 12 glioblastoma patients at Dunedin Hospital using iron-MRI (Ethics reference 17/CEN/176) to showed that iron had no adverse effects. The time post iron administration will be optimized for best MR Imaging in this main study. The pilot study showed that some tumours had additional regions of enhancement and patient survival may also be promoted.

 

The study is led by Neurosurgeon Mr Ahmad Taha along with Dunedin Hospital Radiologists and Researchers at the Otago Medical
School, University of Otago. 

 

This clinical trial is open to those with glioblastoma or brain metastasis from cancers elsewhere in the body. Please contact Neurosurgeon Mr Ahmad Taha at Dunedin Hospital or Dr Noelyn Hung  for further information on 03 477-9669 during office hours.

We are always on the look out to connect patients with clinical trial opportunities. If you have a new treatment for brain tumours, and have the required ethical status in New Zealand to conduct your study, please contact us and we will try to help. We are particularly interested in new glioblastoma treatments or regimes. NZBTTemail@gmail.com
Skip to content